managing the group's assets
A fully dedicated team to support the sustainable growth of Debiopharm Group.
The main objectives are the preservation of capital of Debiopharm Group, and the generation of regular financial incomes for Debiopharm Group's companies.
President Debiopharm Group
Mr Mauvernay received his Master of Science in Economics in 1975. He then obtained a degree (MBA) from the 'Institut d'Administration des Entreprises’ and a DESS in Marketing (Master II Degree) in Clermont-Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he later sold but continued to manage until July 2001, when he joined Debiopharm SA as Executive Vice President with direct responsibilities for the Finance and Administration Department. In 2006, Mr Mauvernay handed over his operational activities within Debiopharm SA and has since been focusing on the administration, finance and strategy of Debiopharm Group. Since 2012 he is Delegate of the Board of Debiopharm Group.
CEO, Debiopharm Investment S.A., President of Strategic Committee Debiopharm Investment
Mrs Calvayrac graduated at the University of Paris (Panthéon-Assas), where she obtained a "Diplôme d'Etudes Supérieures Spécialisées" in Business Law and Tax in 1988 (DESS, currently called "Master II Degree"). She then started a career in the banking sector, and she acquired a broad experience in various positions at Le Crédit Lyonnais (Crédit Agricole Group) in Marketing, Corporate Financing, Retail Banking and Human Resources, before becoming Director of the Financing Department for France, in charge of the Financing for Small Enterprises and of the Real Estate Financing for individuals. She joined Debiopharm Investment SA in April 2008 as General Secretary.
General Secretary
Nicolas Py received his Master’s degree in Cellular Biology and Molecular Genetics from the universities of Versailles and Paris-Sud in 1997, then graduated as an Engineer in Life Sciences and Applied Biochemistry from AgroParisTech Institute in 2000, and completed his education with a Master’s degree in Marketing and Management from EM Strasbourg Business School in 2003. He started his career in 2000 as an analyst at ADIT, a consulting company specialized in Competitive Intelligence (Paris and Strasbourg, France). In 2003, he joined the Business Development department of Transgene (Strasbourg, France), a listed biopharmaceutical company focused on developing targeted immunotherapies. From 2004 to 2007, he worked as Competitive Intelligence analyst at Air Liquide Group (Paris, France), the world leader in gases, technologies and services for industry and health. He joined Debiopharm in 2007 and he is now Director, Head of Market Intelligence.
Member
Director of the IMD World Competitiveness Center, Professor of Finance Arturo Bris is an expert in corporate governance, financial regulation and banking strategy. He led IMD’s Advanced Strategic Management open enrollment program from 2009-2014. Prior to joining IMD, he was a professor at the Yale School of Management where he twice received the best teaching award. He holds a PhD in Management from INSEAD. As Director of the IMD World Competitiveness Center, Arturo directs the publication of the IMD World Competitiveness Yearbook and is currently strengthening and developing other research and benchmarking services for the center. This includes creating customized competitiveness indices for companies and industries and helping governments prioritize national and regional competitiveness strategies. Arturo’s latest research identifies the relationship between income inequality, social mobility and competitiveness. He has also researched and lectured on the effects of the Euro on the corporate sector and the valuation impact of corporate governance changes. The top journals in finance—Journal of Finance, the Journal of Financial Economics, the Review of Financial Studies, the Journal of Legal Studies and the Journal of Business—have published his work.
Member
Renaud de Planta has been a Managing Partner of the Pictet Group since 1998. He is Chairman of Pictet Asset Management, the Pictet Group's institutional arm, having previously been CEO of this division between 1998 and 2016. He also supervises Group Finance and Treasury. Before joining Pictet, Renaud spent 12 years with UBS. He held various managerial positions there, including being responsible for fixed income derivatives in Zurich before moving to Hong Kong to become CEO of UBS North Asia. He was then appointed Global Head of Equity Derivatives for UBS Warburg in London. Renaud completed his undergraduate and PhD studies in Financial Economics at the University of St. Gallen. He also gained an MBA with a specialisation in Finance at the University of Chicago. He is member of the Board of several Swiss and international academic institutions (SFI, ICMB, University of Chicago Booth) and charitable organisations and foundations.
Member
Ferdinando Mercuri is an equity partner at Deloitte LLP specialized in tax and based in Switzerland. He has a broad experience of the Financial Services Industry and he is responsible for this business line in the Swiss Romande region. He is also advising quoted groups and family-owned businesses in all their tax matters, including restructurings, mergers and acquisitions, relocation of activities inside or outside Switzerland and supply chain changes. Having started his career at Arthur Andersen in 1998, Ferdinando has then held key tax roles at Lenz & Staehelin, Adecco and BNP Paribas, where he developed the internal tax function in Switzerland. In March 2009, he joined Deloitte as a Director and was promoted equity partner in June 2011. Ferdinando is also responsible for the international tax module in Swiss Romande at the Swiss Tax Academy since 2006 and is also teaching at the Haute Ecole d’Ingénierie et de Gestion of the canton of Vaud since 2002. He is also acting as an expert at the Swiss certified tax expert exam since 2008. Ferdinando holds a law degree from the University of Lausanne and is a Swiss Certified Tax Expert since 2002.
Member
Bertrand Rambaud is the Chairman of Siparex Group, one of France’s independent private equity specialists, founded 40 years ago. In 1991 Mr. Rambaud began his career at Siparex Group as Associate, and then as Senior Investment Manager. He subsequently moved to PWC, where he was a Partner in the Transactions Services department from 1997 to 2002. Following that position, he chose to pursue his career at Siparex, where he was appointed Managing Director in 2002. After being named Deputy General Manager in 2005, with joint responsibility for the Growth Capital/LBO activity, he was given a seat on the Management Board in January 2009 and then promoted to Chairman of Siparex Group in July 2009. Bertrand Rambaud is a Board member of Biscuits Bouvard and Lacroix Emballages, as well as a member of the Investment Committee of Mérieux Développement. He holds a degree from EM Lyon.
Member
Charles Ruggieri, doctor of law, founded the Batipart Group, a family-owned holding, in 1988. After entering the real estate sector of the steel industry in 1970, he headed up the sector until Immobilière Batibail was privatised in 1987. In 1999, he completed the merger of Batibail and Gecina, the first French land corporation. Moreover, he developed the Batigère group, a real estate group focusing on low-income housing, which he managed between 1985 and 1995. In 2000, he created the Foncière des Régions, becoming one of Europe’s leading real estate companies with assets worth €18 billion, and chaired the supervisory board from 2001 to 2010. At the same time, he created an additional arm to the company in 2001 focussing on dependent elderly persons, gradually developing the Korian-Medica Group, a European leader in retirement homes (nursing homes). Since 2011, Batipart has been developing another real estate company, Eurosic, the assets of which rose from €1.2 billion to almost €8 billion in 2017. Batipart sold its shares in that company in September 2017 to refocus on its real estate activities on Europe. In addition, the Batipart Group has diversified its activities on an international scale with the development of a hotel group in Africa under its own name (ONOMO) along with a real estate platform in North America (Canada).
CEO, Debiopharm Investment S.A.
Mrs Calvayrac graduated at the University of Paris (Panthéon-Assas), where she obtained a "Diplôme d'Etudes Supérieures Spécialisées" in Business Law and Tax in 1988 (DESS, currently called "Master II Degree"). She then started a career in the banking sector, and she acquired a broad experience in various positions at Le Crédit Lyonnais (Crédit Agricole Group) in Marketing, Corporate Financing, Retail Banking and Human Resources, before becoming Director of the Financing Department for France, in charge of the Financing for Small Enterprises and of the Real Estate Financing for individuals. She joined Debiopharm Investment SA in April 2008 as General Secretary.
Director, Real Estate department, Debiopharm Investment S.A.
Mr. Favre obtained a Federal Diploma of Property Management in 2007 followed by an Advanced Federal Diploma of Real Estate Management in 2013. With 15 years' experience in real estate, he has held several management positions in life insurance and real estate management companies. Starting in 2010 he spent 6 years at Solvalor Fund Management SA where he subsequently worked as Property Manager, then Real Estate Manager, and subsequently Deputy Director. He joined Debiopharm Investment in 2017.
Director, Private Equity Department, Debiopharm Investment S.A.
Mrs Le Coz Sanchez obtained in 1998 a master II degree from the University of Paris-La Sorbonne: DESS "Information and Decision Techniques in the Enterprise". She has completed her education by becoming a CFA® charterholder. Alexandra has previously worked in different leading multinational companies where she was responsible for Planning, Forecasting and Budgeting. She joined Debiopharm Investment in May 2010 as Financial Analyst. Since 2012, she has headed the Private Equity activities as part of investments diversification strategy. She serves on the Board of Directors of various companies in the portfolio and on some Funds' Advisory Committees.
Chief Investment Officer, Financial department, Debiopharm Investment S.A.
Mr Moulin obtained a BA in International Relations in Geneva in 1991 (IUHEI), completed by a Postgrade Diploma in Economics from the London School of Economics and Political Science in 1993. He received the Federal Diploma for financial analyst and portfolio manager in 1998. He successively worked at Swiss Bank Corporation/UBS, Bank Morgan Stanley and Schroder & Co Banque SA, where he held several leading and strategic positions in investment strategy, asset allocation, portfolio management and financial analysis. He joined Debiopharm Investment in June 2014.
Debiopharm Investment S.A.
Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
1002 Lausanne
Switzerland
Tel. +41 (0)21 331 29 30
Fax +41 (0)21 331 29 31
© 2018 Debiopharm Group™
